Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company
· Coming Phase I/IIa basket trial planned to include five select cancer indications · Study will apply Curasight’s uPAR theranostic platform approach combining diagnosis (uTRACE[®]) and therapy (uTREAT[®]) · First patients expected to be dosed in the beginning of 2025 with expected first efficacy data in 2025. Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer